JPM

Jessica Fye

Q: How accurate are Jessica Fye's stock ratings?

About 57% of Jessica's ratings were profitable over a one-year hold, with an average return of +3.6% per rating, measured by 13Foresight from historical prices.

Q: How is Jessica ranked?

Jessica Fye is ranked #1792 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

J.P. Morgan

Wall Street Analyst

★★★☆☆

#1792

on 13Foresight · ranked by our own returns

54%

Success Rate

+3.0%

Average Return

43 of 80 calls profitable · +28.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 54% of Jessica Fye's ratings turned a profit when each position was held for 1 year — averaging +3.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

57 Buy 19 Hold 11 Sell

Jessica's Stock Coverage 36 ratings · 2026-09-12

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
VRTX Vertex Pharmaceuticals	Sep 11, 2026	BUY	Strong Buy -13.6% avg upside 62 analysts	$560.00 8.58% Upside	·	·
ASND Ascendis Pharma	Aug 31, 2026	BUY	Strong Buy +8.0% avg upside 26 analysts	—	+2.9%	·
IMCR Immunocore Holdings	Aug 21, 2026	BUY	Strong Buy +97.1% avg upside 22 analysts	$50.00 53.37% Upside	-8.9%	·
STOK Stoke Therapeutics	Aug 21, 2026	BUY	Strong Buy +40.6% avg upside 18 analysts	$40.00 37.86% Upside	-10.1%	·
MRNA Moderna	Aug 21, 2026	SELL	Hold -32.6% avg upside 38 analysts	$77.00 46.42% Downside	+0.8%	·
NKTR Nektar Therapeutics	Aug 21, 2026	HOLD	Strong Buy +9.6% avg upside 26 analysts	$65.00 6.88% Downside	-5.8%	·
AMRN Amarin	Aug 21, 2026	SELL	Hold -37.4% avg upside 18 analysts	$13.00 5.72% Downside	+0.4%	·
EBS Emergent Biosolutions	Aug 21, 2026	SELL	Buy +301.2% avg upside 9 analysts	—	-22.6%	·
MBX MBX Biosciences, Inc.	Aug 21, 2026	BUY	Strong Buy +34.5% avg upside 14 analysts	$88.00 49.20% Upside	-8.1%	·
BNTX BioNTech SE	Aug 19, 2026	HOLD	Strong Buy +38.5% avg upside 26 analysts	—	-8.3%	·
AKTS Aktis Oncology, Inc.	Aug 14, 2026	BUY	Strong Buy +42.0% avg upside 11 analysts	$33.00 41.62% Upside	-6.5%	·
MIRM Mirum Pharmaceuticals	Aug 11, 2026	BUY	Strong Buy +15.0% avg upside 22 analysts	$118.00 20.05% Upside	+0.1%	·
DNLI Denali Therapeutics	Aug 11, 2026	BUY	Strong Buy +83.5% avg upside 24 analysts	$29.00 37.43% Upside	-9.8%	·
IONS Ionis Pharmaceuticals	Aug 10, 2026	BUY	Strong Buy +42.3% avg upside 43 analysts	$76.00 40.13% Upside	-4.8%	·
INSM Insmed	Aug 10, 2026	BUY	Strong Buy +36.7% avg upside 37 analysts	$175.00 35.25% Upside	-4.0%	·
JAZZ Jazz Pharmaceuticals	Aug 04, 2026	BUY	Strong Buy -2.2% avg upside 35 analysts	$276.00 12.30% Upside	-6.0%	·
ALNY Alnylam Pharma	Aug 04, 2026	BUY	Strong Buy +30.3% avg upside 51 analysts	$375.00 50.81% Upside	+13.6%	·
INCY Incyte	Jul 30, 2026	HOLD	Buy -10.2% avg upside 48 analysts	$120.00 1.21% Downside	+3.1%	·
ALKS Alkermes	Jul 29, 2026	HOLD	Strong Buy -9.6% avg upside 34 analysts	$61.00 32.78% Upside	-4.6%	·
ONC BeOne Medicines	Jul 23, 2026	BUY	Strong Buy +4.7% avg upside 28 analysts	$425.00 22.74% Upside	+9.6%	·
UTHR United Therapeutics	Jul 23, 2026	BUY	Buy -13.6% avg upside 26 analysts	$687.00 38.13% Upside	-6.1%	·
BCRX BioCryst	Jul 13, 2026	HOLD	Strong Buy +122.1% avg upside 24 analysts	$12.00 47.73% Upside	-18.1%	·
LEGN Legend Biotech	Jul 13, 2026	HOLD	Strong Buy +232.0% avg upside 27 analysts	$35.00 87.81% Upside	-26.9%	·
NVCR NovoCure	Jul 13, 2026	HOLD	Strong Buy +217.9% avg upside 11 analysts	$17.00 9.66% Upside	-3.6%	·
HALO Halozyme	Oct 27, 2025	HOLD	Buy -39.3% avg upside 20 analysts	$65.00 39.38% Downside	+62.5%	·
BMRN BioMarin Pharmaceutical	Oct 27, 2025	BUY	Strong Buy +45.6% avg upside 52 analysts	—	+24.7%	·
SRRK Scholar Rock Holding	Oct 13, 2025	BUY	Strong Buy +5.6% avg upside 23 analysts	—	+61.7%	·
ZYME Zymeworks	Jun 07, 2022	HOLD	Strong Buy +27.3% avg upside 25 analysts	$14.00 46.65% Downside	+31.7%	·
LXRX Lexicon Pharmaceuticals	Apr 07, 2022	HOLD	Buy +100.0% avg upside 9 analysts	$5.00 149.91% Upside	-11.9%	·
TVRD Tvardi Therapeutics	Mar 14, 2022	BUY	Strong Buy +833.1% avg upside 24 analysts	$19.00 916.11% Upside	·	·
APRE Aprea Therapeutics	Aug 20, 2021	SELL	Strong Buy +2851.8% avg upside 7 analysts	—	·	·
DNTH Dianthus Therapeutics	Aug 03, 2021	HOLD	Strong Buy -3.4% avg upside 31 analysts	$7.00 93.33% Downside	-74.2%	·
KLDO Kaleido Biosciences	Oct 14, 2020	SELL	Buy +13249900.0% avg upside 5 analysts	$10.00 9999900.07% Upside	·	·
YUM Yum! Brands	Apr 06, 2020	HOLD	Buy +9.4% avg upside 38 analysts	$66.00 53.15% Downside	+65.0%	·
NVAX Novavax	Mar 19, 2018	SELL	Buy +144.9% avg upside 20 analysts	—	+73.7%	·
ENTA Enanta Pharmaceuticals	Feb 08, 2018	HOLD	Buy +153.4% avg upside 17 analysts	$95.00 632.99% Upside	+21.4%	·

🔒 31 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Jessica Fye — Frequently Asked Questions

How accurate are Jessica Fye's stock ratings?

Based on the calls 13Foresight could measure, about 57% of Jessica's ratings were profitable over a one-year hold, with an average return of +3.6% per rating, or +29.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Jessica ranked on 13Foresight?

Jessica Fye is currently ranked #1792 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Jessica cover?

Jessica most recently has ratings on VRTX, ASND, IMCR, STOK, MRNA, NKTR, AMRN, EBS, MBX, BNTX, AKTS, MIRM and 24 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Jessica Fye

Rating Distribution

Welcome to 13Foresight!